Karyopharm Therapeutics (NASDAQ:KPTI) Issues Earnings Results, Misses Estimates By $0.95 EPS

Karyopharm Therapeutics (NASDAQ:KPTI) posted its earnings results on Thursday. The company reported ($2.32) EPS for the quarter, missing the consensus estimate of ($1.37) by ($0.95), FiscalAI reports. The company had revenue of $33.43 million for the quarter, compared to analyst estimates of $32.19 million.

Here are the key takeaways from Karyopharm Therapeutics’ conference call:

• Myelofibrosis sNDA remains on track for August 2026 under the FDA’s Accelerated Approval pathway, supported by rapid, deep, and sustained spleen-volume responses in the SENTRY trial and constructive FDA discussions.
• If approved, selinexor plus ruxolitinib could become the first approved combination therapy for myelofibrosis, with a potential launch as early as the first quarter of 2027 and estimated U.S. peak annual revenue of approximately $1 billion.
• Liquidity remains a significant risk: Karyopharm had $65.4 million in cash and investments at quarter-end, expects funding only into September 2026, and faces a $16.8 million term-loan payment on September 10 that could trigger a covenant breach without new financing, a waiver, or a strategic transaction.
• The company is reducing investment in endometrial cancer after the XPORT-EC-042 Phase III trial failed to reach statistical significance, while focusing resources on myelofibrosis and multiple myeloma; XPOVIO U.S. revenue nevertheless rose to $30.8 million from $29.7 million year over year.

Karyopharm Therapeutics Stock Up 1.5%

KPTI opened at $2.02 on Friday. Karyopharm Therapeutics has a twelve month low of $1.80 and a twelve month high of $10.99. The company has a fifty day moving average of $7.47 and a 200-day moving average of $7.85. The stock has a market cap of $45.77 million, a PE ratio of -0.15 and a beta of 0.89.

Hedge Funds Weigh In On Karyopharm Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of KPTI. Walleye Capital LLC acquired a new stake in Karyopharm Therapeutics during the 4th quarter worth about $704,000. Bridgeway Capital Management LLC raised its position in shares of Karyopharm Therapeutics by 88.9% in the 4th quarter. Bridgeway Capital Management LLC now owns 65,873 shares of the company’s stock worth $485,000 after acquiring an additional 31,000 shares in the last quarter. Quadrature Capital Ltd acquired a new position in shares of Karyopharm Therapeutics in the 4th quarter valued at about $439,000. State Street Corp boosted its position in shares of Karyopharm Therapeutics by 27.2% during the 4th quarter. State Street Corp now owns 58,942 shares of the company’s stock valued at $434,000 after purchasing an additional 12,600 shares in the last quarter. Finally, Royal Bank of Canada boosted its position in shares of Karyopharm Therapeutics by 761.3% during the 4th quarter. Royal Bank of Canada now owns 58,000 shares of the company’s stock valued at $427,000 after purchasing an additional 51,266 shares in the last quarter. Institutional investors and hedge funds own 66.44% of the company’s stock.

Analyst Upgrades and Downgrades

KPTI has been the subject of several analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Karyopharm Therapeutics in a research note on Tuesday, June 9th. Robert W. Baird downgraded Karyopharm Therapeutics from an “outperform” rating to a “neutral” rating and set a $3.00 price objective for the company. in a report on Friday, July 31st. Wall Street Zen downgraded Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings upgraded Karyopharm Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $16.00 price objective on shares of Karyopharm Therapeutics in a research report on Tuesday, July 21st. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $11.50.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.